AnaptysBio Balance Sheet Health

Financial Health criteria checks 5/6

AnaptysBio has a total shareholder equity of $88.1M and total debt of $310.8M, which brings its debt-to-equity ratio to 352.8%. Its total assets and total liabilities are $452.4M and $364.3M respectively.

Key information

352.8%

Debt to equity ratio

US$310.81m

Debt

Interest coverage ration/a
CashUS$390.90m
EquityUS$88.10m
Total liabilitiesUS$364.29m
Total assetsUS$452.39m

Recent financial health updates

Recent updates

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24
AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27
Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Sep 14
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Sep 12

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

Sep 01
AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Aug 31

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10
Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11
AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Jul 28
AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 09
Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

AnaptysBio EPS beats by $0.03, beats on revenue

May 04

Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

Mar 10
Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 28
AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results

Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth

Feb 10
Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth

Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters

Dec 19
Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters

AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside

Nov 30

AnaptysBio (ANAB) Investor Presentation - Slideshow

Nov 18

Financial Position Analysis

Short Term Liabilities: ANAB's short term assets ($406.8M) exceed its short term liabilities ($37.4M).

Long Term Liabilities: ANAB's short term assets ($406.8M) exceed its long term liabilities ($326.8M).


Debt to Equity History and Analysis

Debt Level: ANAB has more cash than its total debt.

Reducing Debt: ANAB's debt to equity ratio has increased from 1.6% to 352.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANAB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ANAB has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 15.1% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.